Almirall at the JPMorgan Conference - Entering a New Era of Sustained Growth
Almirall, a global pharmaceutical company dedicated to medical dermatology, is participating in the 2025 JPMorgan HealthCare Conference to provide an update on its business strategy and outlook. The company’s CEO and president Carlos Gallardo will highlight a new era for its business starting in 2025 – forecasting sustained double-digit growth of net sales (CAGR 2023-2030) and a substantial margin expansion, driven by Almirall’s focus on medical dermatology, commercial excellence, and its continued investment in R&D to innovate and advance science.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250113044812/en/
Almirall HQ in Barcelona (Photo: Business Wire)
Almirall combines the strengthening of its growth drivers, particularly the biologics products, with the continued growth of its broad portfolio of medical dermatology solutions, including Klisyri®, Wynzora®, and Seysara®. Almirall’s commercial excellence has been demonstrated by the successful launches of biologics across key markets in Europe. The success of the key growth drivers of Almirall has enabled the company to adjust the anticipated peak sales figures for the biologics portfolio to more than 800MM Eur annually comprising of expected peak sales for Ebglyss® of above 450MM Eur, and Ilumetri® of above 300MM Eur.
This development sees Almirall at a turning point entering an era of sustained double-digit growth (net sales CAGR 2023-2030) that is enabled by the previous investments into commercial capabilities for the launch of breakthrough assets, into capabilities, expertise, and infrastructure. This growth will mainly be driven by biologics which are well placed to take significant market share in these segments that show sustained overall increase and a transition of more patients to advanced treatment options.
Importantly, Almirall will continue to invest in its leading R&D capabilities in medical dermatology driving science leadership and enabling the company to develop disruptive and innovative products that build sustainable future growth as a leader in medical dermatology.
Medical Dermatology: Significant unmet needs and growth potential
Medical dermatology continues to be a pharmaceutical sector with significant unmet needs based on the severe patient impact of a wide range of dermatological diseases, the many uncontrolled patients with chronic diseases, increasing numbers of diagnoses, and the transition of more patients to advanced treatments. Almirall has significant potential for growth in this sector due to its dedication to medical dermatology, commercial capabilities, close collaboration with the medical community, and its proven end-to-end capabilities across the entire value chain. This enables Almirall to give patients and the medical community access to innovative and relevant solutions and contribute to improving their lives.
The company has continuously invested around 12% of its Net Sales in R&D over many years, laying the foundation for continued growth and acceleration in the future and creating and advancing a strong pipeline in key areas, both in clinical and preclinical stages.
Almirall has a broad range of collaborations that help to advance science and enable the development of disruptive new treatments across different modalities. The company continues to focus on building collaborations with partners that have new platforms and technologies to further develop its innovative pipeline. We access the latest available technologies, including small molecules, biologics, and other modalities such as mRNA, for example through the multi-target alliance with etherna to discover and develop innovative and disruptive mRNA / LNP therapies.
"2025 is a turning point for Almirall as we are entering an era of sustained double-digit growth of our net sales CAGR to 2030, and increased EBITDA margins to around 25% by 2028. We are dedicated to improving patients' lives and advancing medical dermatology through our leading research and development initiatives and giving patients access to novel and impactful treatment options – now and in the future," stated Carlos Gallardo, CEO and President of Almirall. "We continue with our sustained investment in R&D to lead science, innovation and excellence in medical dermatology. Almirall is a partner of choice for dermatologists and together we will impact more patients' lives in line with our company’s growth.”
“Our robust financial situation enables us to invest in long-term growth opportunities which are aligned with our business strategy and ambition as leaders in medical dermatology. By building on our strong portfolio, and making strategic investments, we are well-positioned to meet our ambitious objectives and generate long-term value for shareholders. Our primary advantage lies in our collaborative mindset, agility, and ability to seize opportunities swiftly. This approach also allows us to distribute development costs efficiently,” stated Mike McClelllan, Almirall's CFO.
About Almirall
Almirall is a global pharmaceutical company dedicated to medical dermatology. We closely collaborate with leading scientists, healthcare professionals, and patients to deliver our purpose: to transform the patients' world by helping them realize their hopes and dreams for a healthy life. We are at the forefront of science to deliver ground-breaking, differentiated medical dermatology innovations that address patients´ needs.
Almirall, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM, total revenue in 2023: €898.8 MM, 1900 employees globally). Almirall products help to improve the lives of patients every day and are available in over 100 countries.
For more information, please visit almirall.com
Disclaimer
This document includes only summary information and does not intend to be comprehensive. Facts, figures and opinions contained herein, other than historical, are "forward-looking statements". These statements are based on currently available information and on best estimates and assumptions believed to be reasonable by the Company. These statements involve risks and uncertainties beyond the Company's control. Therefore, actual results may differ materially from those stated by such forward-looking statements. The Company expressly disclaims any obligation to review or update any forward-looking statements, targets or estimates contained in this document to reflect any change in the assumptions, events or circumstances on which such forward-looking statements are based unless so required by applicable law.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250113044812/en/
Contacts
Corporate Communications:
corporate.communication@almirall.com
Phone: (+34) 659 614 173
Investor Relations:
investors@almirall.com
Phone: (+34) 93 291 30 87
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Duravant to Acquire Pattyn, Provider of Packaging Automation Systems for Bulk and Industrial Applications7.2.2025 15:00:00 CET | Press Release
Duravant LLC (“Duravant”), a global engineered equipment and automation solutions provider to the food processing, packaging and material handling sectors, announced today that it has entered into a definitive agreement to acquire the Pattyn Group BV (‘Pattyn”), a designer and manufacturer of automation systems specializing in B2B packaging. Pattyn is recognized as the premier leader for delivering comprehensive automation solutions and value-added services for bag-in-box packaging applications. Headquartered in Bruges, Belgium, Pattyn has over 70 years of expertise in machinery design and turnkey systems for counting, weighing, filling, and packing technologies for food, ingredients, and various non-food sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207117623/en/ “We are extremely excited to partner with Pattyn,” said Mike Kachmer, Chairman and CEO of Duravant. “Pattyn has a rich history delivering high quality
Leclanché and Pinnacle Advance Strategic Partnership – Milestone Reached with Successful Completion of Due Diligence7.2.2025 09:50:00 CET | Press Release
Ad hoc announcement pursuant to Art. 53 LR Leclanché SA (SIX: LECN), a global leader in energy storage solutions, specialised in heavy duty batteries for Marine and Rail customers, is pleased to announce that Pinnacle International Capital Limited has completed the legal, financial and technical due diligence of the Leclanché group to its satisfaction, thereby fulfilling a key condition on the way to the implementation of the strategic partnership. As a next step in the transaction, Pinnacle will conduct an engineering review. The engineering review aims to optimise the agreed business plan and investment. At the same time, Leclanché will be working through an agreed workplan to address the due diligence items that were identified, with the goal of improving the starting point for the strategic partnership and the investment by Pinnacle. Through this transformative strategic partnership, Pinnacle’s investment will help unlock the strategic growth funding required to support Leclanché’s
Salience Labs Closed Series A Round Led by Applied Ventures and ICM HPQC Fund7.2.2025 09:14:00 CET | Press Release
Salience Labs Limited, a leader in photonic solutions targeting connectivity for AI datacenter infrastructure, today announced the successful close of $30 million in Series A financing led by ICM HPQC Fund and Applied Ventures, LLC, the venture capital arm of Applied Materials, Inc., to further the development of its optical switches for large scale AI connectivity. Applied Ventures and ICM HPQC Fund are joined by Strategic Investment Fund, Braavos, and continued participation from existing investors Oxford Sciences Enterprises, Cambridge Innovation Capital, and leaders from the global semiconductor industry including Silicon Catalyst and Jalal Bagherli. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250207290130/en/ Image by Shabbir Bashar “What our customers want is a photonic switch to connect their AI clusters that is compatible with existing infrastructure while delivering high bandwidth, low latency and significant pow
Japan Sake and Shochu Makers Association Announces 2024 Sake Export Data: Record-High Exports to 80 Countries, Up 6% YoY7.2.2025 04:00:00 CET | Press Release
2024 Sake Export Performance This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250205320328/en/ More people around the world are enjoying Japanese sake (Photo: Business Wire) The Japan Sake and Shochu Makers Association (JSS) has released 2024 sake export data. The total export value reached JPY 43.5 billion, a +6% increase from the previous year, with 3.45 million cases (9L equivalent) shipped to a record 80 countries. Since 2020, export value has grown 1.8 times, the average unit price increased 1.3 times, and the number of export destinations expanded by 19. Premium sake markets have seen significant growth in the past five years. Regionally, Asia accounted for 61% of total export value but saw a slight decline YoY. However, South Korea recorded a notable 29% growth, while Thailand and Malaysia also performed well. North America saw a 27% increase, driven by fine-dining adoption. Western Europe grew 18% YoY, expanding 2.5 ti
DNIB.com Reports Internet Has 364.3 Million Domain Name Registrations at the End of the Fourth Quarter of 20246.2.2025 23:19:00 CET | Press Release
VeriSign, Inc. (NASDAQ: VRSN), a global provider of critical internet infrastructure and domain name registry services, today announced that, according to the latest Domain Name Industry Brief Quarterly Report from DNIB.com, the fourth quarter of 2024 closed with 364.3 million domain name registrations across all top-level domains (TLDs), an increase of 2.0 million domain name registrations, or 0.5% compared to the third quarter of 2024. Domain name registrations also increased by 4.4 million, or 1.2%, year over year. The .com and .net TLDs had a combined total of 169.0 million domain name registrations in the domain name base at the end of fourth quarter of 2024, a decrease of 0.5 million domain name registrations, or 0.3% compared to the third quarter of 2024. The .com and .net TLDs had a combined decrease of 3.7 million domain name registrations, or 2.1%, year over year. As of Dec. 31, 2024, the .com domain name base totaled 156.3 million domain name registrations and the .net domai
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom